Yes, formoterol is available as a dry powder inhaler (DPI).
Formoterol is available in multiple DPI formulations, including a 12 mcg single-use capsule formulation for adults and adolescents, dosed every 12 hours 1. This has been established in FDA-approved products and major asthma guidelines.
Available Formoterol DPI Formulations
Monotherapy Options
- Formoterol DPI 12 mcg/single-use capsule: Approved for adults and adolescents ≥12 years, administered every 12 hours 1
- The FDA label confirms formoterol is available as a dry powder formulation, though it also notes nebulizer solutions exist 2
Combination Products (ICS + Formoterol)
Budesonide/formoterol DPI is widely available and extensively studied:
- Approved for patients ≥12 years of age 1
- Dosing for children 5-12 years is based on clinical trials using DPI formulations 1
- This combination is recommended as preferred therapy in current guidelines for moderate-to-severe asthma 3, 4, 5
Clinical Evidence Supporting DPI Formoterol
Multiple studies demonstrate DPI formoterol is as effective as other delivery systems:
- Pediatric use: DPI formoterol delivered via mechanical actuation with spacer provided rapid bronchodilation and sustained bronchoprotection for at least 8 hours in children as young as 2-5 years 6
- Equivalence studies: DPI formoterol shows comparable efficacy, pharmacokinetics, and systemic effects to both CFC and HFA metered-dose inhalers 7
- COPD applications: Glycopyrronium/formoterol DPI demonstrated significant improvements in lung function and quality of life in moderate-to-severe COPD 8
Important Clinical Considerations
DPIs require adequate inspiratory flow to be effective, which is a consideration for:
- Young children (typically <4-5 years)
- Patients during acute severe exacerbations
- Elderly patients with reduced inspiratory capacity
However, recent guidelines increasingly favor DPIs as first-line options 9 because:
- Most patients prefer multi-dose DPIs when offered a choice 9
- DPIs include dose counters, reducing waste
- Lower environmental carbon footprint compared to MDIs
- Real-world studies generally favor DPIs over MDIs for clinical outcomes 9
Current best practice: For adults and adolescents with asthma requiring step 3-4 therapy, the preferred regimen is maintenance-and-reliever therapy (MART) with ICS-formoterol, which is predominantly available as DPI formulations 3, 4, 5.